The BCG tuberculosis vaccine also strengthens the immune system against malaria. This is what researchers at Radboud university medical center discovered. Their results were published in Nature Communications.Publication: link.
The group led by Mihai Netea, theme Infectious diseases and global health, previously demonstrated that a BCG vaccination, the vaccine against tuberculosis, can 'train' the cells of the congenital immune system to act against other pathogenic microorganisms. For example, early vaccination with the BCG vaccine reduces child mortality, mainly by reducing serious infections. BCG was discovered as early as the 1920s and is one of the most widely used vaccines worldwide. In the Netherlands, the vaccine is not included in the national vaccination program.
"There were indications that BCG could also protect against malaria, but this had not yet been demonstrated in humans," says Robert Sauerwein, theme Infectious diseases and global health. "Because we have more than ten years of experience in the controlled contamination of healthy volunteers with malaria, this seemed a unique opportunity to test the effect of the BCG vaccine on the development of malaria infection." In a controlled study, ten volunteers received the BCG vaccine, and ten volunteers were not vaccinated; five weeks later, they were all stung by malaria mosquitoes.
BCG vaccine also influences the resistance to malariaThe volunteers were closely monitored after exposure to infected mosquitoes and treated immediately if any malaria parasites were found in the blood. "All volunteers developed malaria, but we saw that the immune system was activated more quickly in half of the BCG vaccinated volunteers to fight the malaria infection. As a result, they were better able to control the malaria parasite,” according to physician-researchers Jona Walk and Charlotte de Bree.
"The so-called natural-killer (NK) cells of the innate immune system, in particular, reacted more quickly to the malaria infection in those with a BCG vaccination.” This is an important finding because NK cells remove malaria parasites from the blood, and can thus provide protection against the disease.
The futureAlthough the BCG vaccine did not provide full protection against malaria in this study, there are clear indications that 'BCG-trained immunity' can strengthen the defence against malaria. Because there is no malaria vaccine so far that provides complete protection, the researchers want to see if BCG could strengthen the effect of a vaccine. A vaccination strategy combining BCG and a malaria vaccine seems an attractive prospect.
Related news items
KWF Roadshow 11 November 201910 October 2019
In which way(s) can KWF provide optimal support to oncological research and care? How can we maximize impact on our investments? These questions are pivotal in Ambition 2030: the vision that KWF developed in close cooperation with stakeholders in the oncological field.read more
A personal touch of Frank Wagener10 October 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Frank Wagener.read more
More than 3000 visitors at Open Day RIHS10 October 2019
On Sunday 6 October RIHS organized an Open Day in the Weekend of Science (“Weekend van de Wetenschap”) with special guest and television presenter Klaas van Kruistum. More than 3000 visitors became a health scientist for one day and discovered how special healthcare research is.read more
Dorine Swinkels collaborates with winners of the Nobel Prize in Physiology or Medicine9 October 2019
The Nobel Prize in Physiology or Medicine 2019 was awarded jointly to William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza for their discoveries of how cells sense and adapt to oxygen availability.read more
Scaling up nanotherapy7 October 2019
Scaling up and translating nanotherapy from pre-clinical work in small animal models to a clinical application is not trivial. Raphael Duivenvoorden, theme Renal disorders, and colleagues, published their results on translating a new nanoimmunotherapy in the journal Science Translational Medicine.read more